Chronic pelvic pain syndrome/bladder pain syndrome: Taking stock, looking ahead: ICI-RS 2011

Neurourology and Urodynamics

Volumn 31, Issue 3, 2012, Pages 375-383

  Hanno, Philip ^a   Andersson, Karl Eric ^b   Birder, Lori ^c   Elneil, Suzy ^d   Kanai, Anthony ^c   Pontari, Michel ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bladder pain syndrome; chronic pelvic pain; guidelines; interstitial cystitis; research

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BOTULINUM TOXIN A; CAPSAICIN; CARBACYCLIN; CHONDROITIN SULFATE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSAN POLYSULFATE; PLACEBO; PREGABALIN; TANEZUMAB;

ANTIBIOTIC THERAPY; BLADDER PAIN SYNDROME; CHRONIC PROSTATITIS; CYSTOSCOPY; DIABETIC NEUROPATHY; FIBROMYALGIA; HUMAN; HYPERBARIC OXYGEN; INTERSTITIAL CYSTITIS; NEUROPATHIC PAIN; NONHUMAN; PAIN; PATIENT SELECTION; PELVIS PAIN SYNDROME; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; REVIEW;

ANIMALS; CHRONIC PAIN; CYSTITIS, INTERSTITIAL; DIAGNOSTIC TECHNIQUES, UROLOGICAL; EVIDENCE-BASED MEDICINE; HUMANS; PAIN MEASUREMENT; PELVIC PAIN; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC;

EID: 84859106161     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22202     Document Type: Review

References (64)

1. Fall M, Hanno P, Nordling J,. Bladder pain syndrome, interstitial cystitis, painful bladder syndrome, and hypersensitive bladder syndrome: New nomenclature/new guidelines. Curr Bladder Dysfunct Rep 2012; DOI: 10.1007/s11884-011-0098-3.
2. Van De Merwe J, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: An ESSIC proposal. Eur Urol 2008; 53: 60-7;.
3. Fall M, Baranowski AP, Elneil S, et al. EAU guidelines on chronic pelvic pain. Eur Urol 2010; 57: 35-48;.
4. Fall M, Johansson SL, Aldenborg F,. Chronic interstitial cystitis: A heterogeneous syndrome. J Urol 1987; 137: 35-8;.
5. Johansson SL, Fall M,. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J Urol 1990; 143: 1118-24;.
6. Koziol JA, Adams HP, Frutos A,. Discrimination between the ulcerous and the nonulcerous forms of interstitial cystitis by noninvasive findings. J Urol 1996; 155: 87-90;.
7. Peeker R, Fall M,. Toward a precise definition of interstitial cystitis: Further evidence of differences in classic and nonulcer disease. J Urol 2002; 167: 2470-2;.
8. Theoharides TC, Pang X, Letourneau R, et al. Interstitial cystitis: A neuroimmunoendocrine disorder. Ann N Y Acad Sci 1998; 840: 619-34;.
9. Hanno P, Lin AT, Nordling J, et al. Bladder pain syndrome. In:, Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. Paris, France: Health Publication Ltd; 2009. 1459-518;.
10. Homma Y, Ueda T, Tomoe H, et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int J Urol 2009; 16: 597-615;.
11. Hanno PM, Burks DA, Clemens JQ, et al. AUA Guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol 2011; 185: 2162-70;.
12. Krieger JN, Nyberg L, Nickel J,. NIH consensus definition and classification of prostatitis. JAMA 1999; 3: 236-7;.
13. Schaeffer AJ, Knauss J, Landis JR, et al. Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: The National Institutes of Health Chronic Prostatitis Cohort Study. J Urol 2002; 168: 1048-53;.
14. Schaeffer A, Landis JR, Knauss J, et al. Demographic and clinical characteristics of men with chronic prostatitis: The National Institutes of Health Chronic Prostatitis Cohort Study. J Urol 2002; 168: 593-8;.
15. Litwin MS, McNaughton-Collins M, Fowler FJ, et al. The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure. J Urol 1999; 162: 369-75;.
16. Shoskes DA, Nickel JC, Rackley RR, et al. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: A management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis 2009; 12: 177-83;.
17. Anothaisintawee T, Attia J, Nickel JC, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis. JAMA 2011; 305: 78-86;.
18. Pontari M, Krieger JN, Litwin MS, et al. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: A randomized controlled trial. Arch Intern Med 2010; 170: 1586-93;.
19. Anderson RU, Wise D, Sawyer T, et al. 16-day intensive treatment protocol for refractory chronic prostatitis/chronic pelvic pain syndrome using myofascial release and paradoxical relaxation training. J Urol 2011; 185: 1294-9;.
20. Shoskes D, Nickel C, Kattan M,. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: A prospective study using UPOINT. Urology 2010; 75: 1249-53;.
21. Nicke JC, Shoskes D,. Phenotypic approach to the management of the chronic prostatitis/chronic pelvic pain syndrome. BJU Int 2010; 106: 1252-63;.
22. Pontari MA, Naughton-Collins M, O'leary MP, et al. A case-control study of risk factors in men with chronic pelvic pain syndrome. BJU Int 2005; 96: 559-65;.
23. Clemens JQ, Link CL, Eggers PW, et al. Prevalence of painful bladder symptoms and effect on quality of life in black, Hispanic and white men and women. J Urol 2007; 177: 1390-4;.
24. Giannantoni A, Porena M, Costantini E, et al. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol 2008; 179: 1031-4;.
25. Liu HT, Kuo HC,. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 2007; 70: 463-8;.
26. Pinto R, Lopes T, Frias B, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2010; 58: 360-5;.
27. Smith CP, Radziszewski P, Borkowski A, et al. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 2004; 64: 871-5;.
28. Kuo HC, Chancellor MB,. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 2009; 104: 657-61;.
29. Kanai A, Roppolo J, Ikeda Y, et al. Origin of spontaneous activity in neonatal and adult rat bladders and its enhancement by stretch and muscarininic agonists. Am J Physiol Renal Physiol 2007; 292: 1065.
30. Kanai A, Zabbarova I, Ikeda Y, et al. Sophisticated models and methods for studying neurogenic bladder dysfunction. Neurourol Urodyn 2011; 30: 658.
31. Ochodnicky P, Cruz C, yoshimura N, et al. Nerve growth factor in bladder dysfunction: Contributing factor, biomarker, and therapeutic target. Neurourol Urodyn 2011; 30: 1227-41;.
32. Teichman JM, Moldwin R,. The role of the bladder surface in interstitial cystitis/painful bladder syndrome. Can J Urol 2007; 14: 3599-607;.
33. Birder L, Hanna-Mitchell A, Mayer EA, et al. Cystitis, co-morbid disorders and associated epithelial dysfunction. Neurourol Urodyn 2011; 30: 668-72;.
34. Keay S,. Cell signaling in interstitial cystitis/painful bladder syndrome. Cell Signal 2008; 20: 2174-9;.
35. Birder LA, Wolf-Johnston A, Chib M, et al. Beyond neurons: Involvement of urothelial and glial cells in bladder function. Neurourol Urodyn 2010; 29: 88-96;.
36. Schnegelsberg L, Sun TT, Cain G, et al. Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity, and changes in urinary bladder function. Am J Physiol 2010; 298: R534-47;.
37. Su X, Leon LA, Wu C, et al. Modulation of bladder function by prostaglandin EP3 receptors in the central nervous system. Am J Physiol Renal Physiol 2008; 295: 994.
38. Ishizuka O, Mattiasson A, Andersson KE,. Prostaglandin E2-induced hyperactivity in normal, conscious rats: Involvement of tachykinins ? J Urol 1995; 153: 2034-6;.
39. Birder LA, Chapple CR,. Part 2: Visceral pain syndromes, chronic pelvic pain/interstitial cystitis. In:, Mayer EA, Bushnell M, editors. Functional pain syndromes: Presentation and pathophysiology. Seattle: IASP Press; 2009. 151-68;.
40. Berry S, Elliott M, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol 2011; 186: 540-4;.
41. Hanno PM, Chapple CR, Cardozo LD,. Bladder pain syndrome/interstitial cystitis: A sense of urgency. World J Urol 2009; 27: 717-21;.
42. Abrams P, Hanno P, Wein A,. Overactive bladder and painful bladder syndrome: There need not be confusion. Neurourol Urodyn 2005; 24: 149-50;.
43. Homma Y,. Lower urinary tract symptomatology: Its definition and confusion. Int J Urol 2008; 15: 35-43;.
44. Dimitrakov J, Kroenke K, Steers WD, et al. Pharmacologic management of painful bladder syndrome/interstitial cystitis: A systematic review. Arch Intern Med 2007; 167: 1922-9;.
45. Liu HT, Tyagi P, Chancellor M, et al. Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 2010; 106: 1681-5;.
46. Evans RJ, Moldwin R, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol 2011; 185: 1716-21;.
47. Sairanen J, Forsell T, Ruutu M,. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol 2004; 171: 2138-41;.
48. Sairanen J, Tammela TL, Leppilahti M, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: A randomized comparative study. J Urol 2005; 174: 2235-8;.
49. Yang CC, Burks D, Propert K, et al. Early termination of a trial of mycophenolate mofetil for treatment ofinterstitial cystitis/painful bladder syndrome: Lessons learned. J Urol 2011; 185: 901-6;.
50. Hurst RE,. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol 1994; 12: 3-10;.
51. Morales A, Emerson L, Nickel JC, et al. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 1996; 156: 45-8;.
52. Nickel JC, Egerdie RB, Steinhoff G, et al. A multicenter, randomized, double-blind, parallel group pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with interstitial cystitis/painful bladder syndrome. Urology 2010; 76: 804-9;.
53. Lee J, Han D, Jeong H,. Bladder pain syndrome treated withtripletherapy with gabapentin, amitriptyline, and a nonsteroidal anti-inflammatory drug. Int Neurourol J 2010; 14: 256-60;.
54. Hader J, Marzella L, Myers R, et al. Hyperbaric oxygen treatment for experimental cyclophosphamide-induced hemorrhagic cystitis. J Urol 1993; 149: 1617-21;.
55. Norkool D, Hampson N, Gibbons R, et al. Hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis. J Urol 1993; 150: 332-4;.
56. Weiss JM, Mattei D, Neville D, et al. Primary treatment of radiation-induced hemorrhagic cystitis with hyperbaric oxygen: 10-year experience. J Urol 1994; 151: 1514-7;.
57. van OA, Rossbach G, Pajonk F, et al. Safety and efficacy of hyperbaric oxygen therapy for the treatment of interstitial cystitis: A randomized, sham controlled, double-blind trial. J Urol 2006; 176: 1442-6;.
58. van Ophoven A, Rossbach G, Oberpenning F, et al. Hyperbaricoxygenfor the treatment of interstitialcystitis: Long-term results of a prospective pilot study. Eur Urol 2004; 46: 108-13;.
59. Tanaka T, Nitta Y, Morimoto K,., et al. Hyperbaric oxygen therapyfor painful bladder syndrome/interstitial cystitis resistant to conventional treatments: Long-term results of a case series in Japan. BMC Urol 2011; 11-6;.
60. Marcelissen T, Jacobs R, van Kerrebroeck PE, et al. Sacral neuromodulation as a treatment for chronic pelvic pain. J Urol 2011; 186: 387-93;.
61. Rudick CN, Berry RE, Johnson J, et al. Uropathogenic Escherichia coli induces chronic pelvic pain. Infect Immun 2011; 79: 628-35;.
62. Farmer M, Chanda M, Parks E, et al. Brain functional and anatomical changes in chronic prostatitis/chronic pelvic pain. J Urol 2011; 186: 117-24;.
63. Nickel JC, Tripp D, Chuai S, et al. Psychosocial variables affect the quality of life of men diagnosed with chronic prostatitis/chronic pelvic pain syndrome. BJU Int 2008; 101: 59-64;.
64. Nickel C, Tripp D, Mullins C,. Development of an evidence-based cognitive behavioral treatment program for men with chronic prostatitis/chronic pelvic pain syndrome. World J Urol 2008; 26: 167-72;.